The Clinical Observation of Bisoprolol for Treatment of 40 cases Dilated Cardiomyopathy

Objective:To evaluate the clinical therapeutic efficacy and safety of Bisoprolol for treatment of dilated cardiomyopathy.Methods:eighty patients with idiopathic dilated cardiomyopathy were randomized to take Bisoprolol (2.5～10mg per day,n=40) and placebo (n=40) on the basis of conventional treatment.Keep on taking drugs for 1～4 years.The mean of follow up periods was 476 days.The efficacy of Bisoprolol was assessed by means of echo cardiograph and clinical symptoms;primary endpoint was mortality during treatment. Result:After Bisoprolol administration for one year,there were more significant improvement in NYHA functional class in Bisoprolol group than in placebo group. During the first year of therapy,Bisoprolol was associated with greater overall reduction of left ventricular end- diastolic diameter from 58.1±6.3 to 53.8±6.5(P0.05)and an overall increase in the LVEF% from 31.8±3.8 to 37.1±3.5(P0.05).After one year treatment,there were 3 deaths in the A group and 4 in B group.Mortality was not significantly different.In the Bisoprolol group,the 2-and 3-years survival rates were 67.5% and 55% respectively, which were significantly higher than those (45% and 25%) in the placebo group(P0.05).Conclusion:Long term addition of Bisoprolol to standard therapy may profoundly improve cardiac function and prognosis and prevent clinical deterioration in patients with idiopathic dilated cardiomyopathy when compared with patients without Bisoprolol treatment.